Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 36.69M | 25.38M | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 34.24M | 23.77M | -2.03M | -462.00K | -1.00K | 0.00 |
EBITDA | -145.63M | -173.76M | -196.62M | -248.03M | -226.79M | -65.33M |
Net Income | -142.72M | -169.93M | -198.64M | -234.60M | -234.29M | -65.32M |
Balance Sheet | ||||||
Total Assets | 103.74M | 129.51M | 229.18M | 383.17M | 620.09M | 117.38M |
Cash, Cash Equivalents and Short-Term Investments | 48.08M | 69.35M | 200.64M | 371.99M | 591.42M | 114.99M |
Total Debt | 894.00K | 1.30M | 2.17M | 3.72M | 0.00 | 0.00 |
Total Liabilities | 49.59M | 61.98M | 51.71M | 27.20M | 62.07M | 182.63M |
Stockholders Equity | 54.15M | 67.54M | 177.47M | 355.97M | 558.02M | -65.25M |
Cash Flow | ||||||
Free Cash Flow | -141.55M | -170.63M | -173.78M | -221.69M | -184.82M | -14.57M |
Operating Cash Flow | -141.41M | -170.49M | -173.16M | -219.99M | -184.74M | -14.57M |
Investing Cash Flow | -144.00K | -140.00K | 280.68M | -230.67M | -50.71M | 0.00 |
Financing Cash Flow | 240.00K | 39.33M | 1.04M | 506.00K | 662.68M | 129.56M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $7.50B | 0.31 | -61.87% | 2.27% | 17.10% | 1.59% | |
48 Neutral | $58.32M | ― | -46.28% | ― | -33.00% | 54.91% | |
44 Neutral | $86.73M | ― | -122.69% | ― | ― | 20.91% | |
44 Neutral | $63.12M | ― | 91.63% | ― | -55.47% | 24.92% | |
38 Underperform | $48.14M | ― | -130.16% | ― | ― | 65.54% | |
37 Underperform | $258.25M | ― | -141.69% | ― | ― | -17.06% | |
35 Underperform | $101.70M | ― | -101.34% | ― | ― | 21.40% |
On April 18, 2025, Invivyd, Inc. entered into a $30 million loan agreement with Silicon Valley Bank, allowing for future capital drawdowns contingent on meeting specific conditions and milestones. This non-dilutive financing supports Invivyd’s strategic focus on enhancing per-share value and advancing its pipeline, including the monoclonal antibody candidate VYD2311, which is being developed for COVID-19 treatment and prevention.
Spark’s Take on IVVD Stock
According to Spark, TipRanks’ AI Analyst, IVVD is a Neutral.
Invivyd’s stock is under pressure due to significant financial difficulties, with ongoing losses and cash flow issues. The technical indicators suggest a bearish trend, and the valuation metrics highlight market concerns about future profitability. However, the appointment of Ajay Royan to the board is a positive corporate development that could improve strategic outcomes. Overall, the stock scores low due to financial and technical weaknesses, partially offset by potential strategic improvements.
To see Spark’s full report on IVVD stock, click here.
On March 22, 2025, Invivyd, Inc. appointed Ajay Royan, founder of Mithril Capital, to its Board of Directors, with his term expiring at the 2025 annual meeting of stockholders. Royan, a venture capitalist with a focus on healthcare, technology, and energy, will receive compensation consistent with other non-employee directors and was granted an option to acquire 100,000 shares of common stock. His appointment is expected to enhance Invivyd’s efforts to advance its monoclonal antibody technology platform, which aims to provide high-quality medicines for vulnerable populations affected by COVID-19 and other diseases.